EPISODE · Jul 20, 2021 · 30 MIN
Can Money Buy Health in Heart Failure?
from CEimpact Podcast
A new study evaluates the cost-effectiveness of dapagliflozin in heart failure. Geoff and Jake continue the conversation from "Home Sweet Home (It's Where the Heart Is)" [Previous Episode] about the role of SGLT-2is in heart failure. This time the conversation is focused on the cost-effectiveness and QALYs. Is the price right for improved care?Redeem your CPE or CME credit here!We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964References and resources: Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. Published online May 26, 2021. doi:10.1001/jamacardio.2021.1437Continuing Education Information:Learning Objectives: 1. Define QALY2. Discuss the cost-effectiveness of dapagliflozin in heart failure0.05 CEU | 0.5 HrsACPE UAN: 0107-0000-21-264-H01-PInitial release date: 7/20/21Expiration date: 7/20/2022Complete CPE & CME details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
What this episode covers
A new study evaluates the cost-effectiveness of dapagliflozin in heart failure. Geoff and Jake continue the conversation from "Home Sweet Home (It's Where the Heart Is)" [Previous Episode] about the role of SGLT-2is in heart failure. This time the conversation is focused on the cost-effectiveness and QALYs. Is the price right for improved care? Redeem your CPE or CME credit here! We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155...
NOW PLAYING
Can Money Buy Health in Heart Failure?
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m